Advances in the Diagnosis and Management of Acute Retinal Necrosis.

Annals of Eye Science Pub Date : 2020-09-01 Epub Date: 2020-09-15 DOI:10.21037/aes-2019-dmu-09
Casey L Anthony, J Clay Bavinger, Steven Yeh
{"title":"Advances in the Diagnosis and Management of Acute Retinal Necrosis.","authors":"Casey L Anthony, J Clay Bavinger, Steven Yeh","doi":"10.21037/aes-2019-dmu-09","DOIUrl":null,"url":null,"abstract":"<p><p>Acute retinal necrosis (ARN) is a devastating syndrome characterized by panuveitis, retinal necrosis, and a high rate of retinal detachment that may result in poor visual outcomes if not promptly diagnosed and treated. ARN is most commonly caused by viruses with the herpesvirus family. Etiologies include varicella-zoster virus, herpes simplex virus, and cytomegalovirus, and may be promptly diagnosed by polymerase chain reaction testing of aqueous or vitreous fluid. The true incidence of ARN is not known due to its rarity; as a result, clinical treatment is often guided by retrospective case series, case reports, and expert opinion. Standard of care has evolved over time but currently includes a combination of systemic and intravitreal antiviral in conjunction with topical or oral steroids and surgical therapy as needed. Combination therapy may reduce the rate of severe vision loss and increase the rate of visual acuity gain, although further studies are needed in this area. In particular for patients with mild to moderate disease, combination therapy may reduce the rate of retinal detachment. Adjunctive therapies including oral corticosteroid and prophylactic laser barricade are incompletely studied, but corticosteroid in particular, may reduce inflammation, which also is involved in the severe disease pathogenesis observed in ARN. This review discusses the advances in diagnosis and treatment of ARN, including management with combination antiviral medication and surgical interventions.</p>","PeriodicalId":8400,"journal":{"name":"Annals of Eye Science","volume":"5 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771653/pdf/nihms-1623169.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Eye Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/aes-2019-dmu-09","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/9/15 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Acute retinal necrosis (ARN) is a devastating syndrome characterized by panuveitis, retinal necrosis, and a high rate of retinal detachment that may result in poor visual outcomes if not promptly diagnosed and treated. ARN is most commonly caused by viruses with the herpesvirus family. Etiologies include varicella-zoster virus, herpes simplex virus, and cytomegalovirus, and may be promptly diagnosed by polymerase chain reaction testing of aqueous or vitreous fluid. The true incidence of ARN is not known due to its rarity; as a result, clinical treatment is often guided by retrospective case series, case reports, and expert opinion. Standard of care has evolved over time but currently includes a combination of systemic and intravitreal antiviral in conjunction with topical or oral steroids and surgical therapy as needed. Combination therapy may reduce the rate of severe vision loss and increase the rate of visual acuity gain, although further studies are needed in this area. In particular for patients with mild to moderate disease, combination therapy may reduce the rate of retinal detachment. Adjunctive therapies including oral corticosteroid and prophylactic laser barricade are incompletely studied, but corticosteroid in particular, may reduce inflammation, which also is involved in the severe disease pathogenesis observed in ARN. This review discusses the advances in diagnosis and treatment of ARN, including management with combination antiviral medication and surgical interventions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
急性视网膜坏死诊治进展》。
急性视网膜坏死(ARN)是一种破坏性综合征,其特征是泛眼炎、视网膜坏死和高视网膜脱离率,如果不及时诊断和治疗,可能会导致不良的视力后果。ARN 最常见的病因是疱疹病毒科的病毒。病因包括水痘-带状疱疹病毒、单纯疱疹病毒和巨细胞病毒,可通过对水液或玻璃体液进行聚合酶链反应检测而迅速确诊。由于 ARN 的罕见性,其真实发病率尚不清楚;因此,临床治疗通常以回顾性系列病例、病例报告和专家意见为指导。随着时间的推移,治疗标准也在不断变化,但目前包括全身和玻璃体内抗病毒治疗、局部或口服类固醇以及必要的手术治疗。联合疗法可降低严重视力丧失率,提高视力恢复率,但这方面还需要进一步研究。特别是对于轻度至中度患者,联合疗法可能会降低视网膜脱离的发生率。包括口服皮质类固醇和预防性激光障眼法在内的辅助疗法尚未得到全面研究,但皮质类固醇尤其可以减轻炎症,而炎症也与 ARN 中观察到的严重疾病发病机制有关。本综述讨论了 ARN 诊断和治疗方面的进展,包括联合抗病毒药物治疗和手术干预。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
0
期刊最新文献
Designing a medical ethics curriculum in ophthalmology Medical and surgical approach to ocular surface reconstruction Improving the training abilities of ophthalmic educators: the Ophthalmology Foundation’s initiatives Interactivity software tools for teaching in ophthalmology Review: update on performance assessment and monitoring systems for ophthalmologists
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1